Animal Cell, Per Se (e.g., Cell Lines, Etc.); Composition Thereof; Process Of Propagating, Maintaining Or Preserving An Animal Cell Or Composition Thereof; Process Of Isolating Or Separating An Animal Cell Or Composition Thereof; Process Of Preparing A Composition Containing An Animal Cell; Culture Media Therefore Patents (Class 435/325)
  • Patent number: 9750820
    Abstract: Disclosed is an IgG Fc fragment useful as a drug carrier. A recombinant vector expressing the IgG Fc fragment, a transformant transformed with the recombinant vector, and a method of preparing an IgG Fc fragment are disclosed. When conjugated to a certain drug, the IgG Fc fragment improves the in vivo duration of action of the drug and minimizes the in vivo activity reduction of the drug.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: September 5, 2017
    Assignee: HANMI SCIENCE CO., LTD.
    Inventors: Sung Youb Jung, Jin Sun Kim, Geun Hee Yang, Se Chang Kwon, Gwan Sun Lee
  • Patent number: 9752124
    Abstract: The invention relates to a method for culturing epithelial stem cells, isolated tissue fragments comprising the epithelial stem cells, or adenoma cells, and culturing the cells or fragments in the presence of a Bone Morphogenetic Protein (BMP) inhibitor, a mitogenic growth factor, and a Wnt agonist when culturing epithelial stem cells and isolated tissue fragments. The invention further relates to a cell culture medium comprising a BMP inhibitor, a mitogenic growth factor, and a Wnt agonist, to the use of the culture medium, and to crypt-villus organoids, gastric organoids, pancreatic organoids, liver organoids, colon organoids, Barrett's Esophagus organoids, adenocarcinoma organoids and colon carcinoma organoids that are formed in the culture medium.
    Type: Grant
    Filed: July 29, 2011
    Date of Patent: September 5, 2017
    Assignee: Koninklijke Nederlandse Akademie van Wetenschappen
    Inventors: Toshiro Sato, Johannes C. Clevers, Meritxell Huch Ortega
  • Patent number: 9752118
    Abstract: This disclosure generally relates to cell-based therapies for treatment of visual disorders, including disorders of the cornea. Methods are exemplified for directed differentiation of corneal cells from stem cells. Compositions of corneal endothelial cells and uses thereof are also provided. Exemplary compositions exhibit improved cell density and/or more “youthful” gene expression relative to cells obtained from donated tissue.
    Type: Grant
    Filed: December 6, 2012
    Date of Patent: September 5, 2017
    Assignee: Astellas Institute for Regenerative Medicine
    Inventors: Kathryn L. McCabe, Shi-Jiang Lu, Robert P. Lanza
  • Patent number: 9752190
    Abstract: The present invention relates to a composition for detecting the undifferentiated human pluripotent stem cells comprising an agent useful for measuring the level of Desmoglein 2 (Dsg 2) mRNA or the protein thereof, a kit for detecting the undifferentiated human pluripotent stem cells comprising the said composition, a method for detecting the undifferentiated human pluripotent stem cells containing the step of measuring the level of Desmoglein 2 mRNA or the protein thereof, a method for evaluating the differentiation of human pluripotent stem cells and thereafter for separating the undifferentiated human pluripotent stem cells, a method for reducing the undifferentiated status of human pluripotent stem cells by inhibiting the expression or activation of Desmoglein 2, and a monoclonal antibody binding specifically to human Desmoglein 2.
    Type: Grant
    Filed: July 22, 2015
    Date of Patent: September 5, 2017
    Assignee: Korea Research Institute of Bioscience and Biotechnology
    Inventors: Jeong Ki Min, Jongjin Park, Kwang-Hee Bae, Sang Chul Lee, Yee Sook Cho
  • Patent number: 9745554
    Abstract: The invention relates to the discovery that the proliferation and survival of pancreatic progenitor cells can be enhanced by contacting the cells with, (1) a caspase inhibitor sufficient to reduce apoptosis in the pancreatic endocrine cells; and, (2) a growth factor in an amount sufficient to increase the level of activated Akt in the pancreatic endocrine cells.
    Type: Grant
    Filed: January 18, 2007
    Date of Patent: August 29, 2017
    Assignee: ReNeuron, Inc.
    Inventors: Monica Florio, Aleksandar Francki, Wen-Ghih Tsang
  • Patent number: 9745568
    Abstract: A device for use in laser optical transfection of biological targets including an optofluidic microdevice and a piece of optical glass. The optofluidic microdevice has a central vertical outlet and a microchannel network that includes a plurality of entrapping channels with narrowings. The microchannel network is fused with the optical glass. In one aspect the device is used with a petri dish having an optical window. In another aspect the device is used with a well plate having a plurality of wells and associated optical windows. In a third aspect the device is used with a barrier. Each of the aspects forms a peripheral space around the optofluidic microdevice capable of retaining a live culture of biological targets and material that is desired to be injected into those biological targets. Polymer tubing is inserted into the central vertical outlet which connects the device to an external pump.
    Type: Grant
    Filed: April 18, 2014
    Date of Patent: August 29, 2017
    Inventor: David Fozdar
  • Patent number: 9744515
    Abstract: PFRs for running multiphasic processes are disclosed. The PFRs are single or multi-chamber devices having at least three types of regions (a liquid-contacting region, a gas-contacting region and a Ssquid-coSection region), and a porous substrate providing fluid communication at least between the liquid-contacting and gas-contacting regions. Removal of liquid from the porous substrate, such as by collecting the liquid as it flows off the bottom of the porous substrate in the Siquid-coSSection region or such as by evaporation of the liquid from the porous substrate in the evaporation region supports a continuous flow process. Methods of using the PFRs are also disclosed, for example methods of using the PFRs as photobioreactors for cultivating photosynthetic microorganisms, for producing fermentable sugars, for producing ethanol, for fermenting synthesis gas and producing single cell protein from natural gas.
    Type: Grant
    Filed: November 13, 2012
    Date of Patent: August 29, 2017
    Assignee: Calysta, Inc.
    Inventors: Marc Gregor Von Keitz, Jimmy Lee Gosse, Stefan Thust, Thomas Harwood
  • Patent number: 9738921
    Abstract: Provided herein are compositions and methods for monitoring the movement of analytes and/or cellular components across biological membranes (e.g., cell surface internalization). In particular, reporter constructs are provided, the transmembrane movement of which (e.g., by endocytosis) is monitored by methods described herein.
    Type: Grant
    Filed: July 15, 2015
    Date of Patent: August 22, 2017
    Assignee: Promega Corporation
    Inventors: Brock F. Binkowski, Mei Cong, Matthew B. Robers
  • Patent number: 9732128
    Abstract: The vast differentiation potential of human embryonic and induced pluripotent stem cells, including their potential to cascade through all of the somatic cell lineages and to display the complete transcriptional regulatory network of human biology, has generated interest in deriving scalable, purified, and identified cell types and methods of discovering the precise structure of the human regulatory network. However, the innate capacity of pluripotent cells to display all these lineages is not necessarily reflected during their culture in vitro. The clonal isolation and propagation of progenitors greatly facilitates the generation of highly purified and identified formulations for research and therapeutic purposes.
    Type: Grant
    Filed: October 21, 2011
    Date of Patent: August 15, 2017
    Assignee: BioTime, Inc.
    Inventors: Michael D. West, Karen B. Chapman
  • Patent number: 9725695
    Abstract: The invention provides a defined low protein culture medium for maintaining cells in an undifferentiated state, the medium comprising: a basal medium, an organic acid from the tricarboxylic acid cycle, nonessential amino acids, a combination of growth factors selected from the group consisting of FGF-2 protein, an IGF-1 protein or insulin, a Transferrin protein, and a TGF beta 1 protein, wherein the medium is essentially feeder-free, essentially xeno-free, essentially free of beta-mercaptoethanol, and essentially free of animal-derived or human-derived proteins.
    Type: Grant
    Filed: May 5, 2011
    Date of Patent: August 8, 2017
    Assignees: The Regents of the University of California, Universidade Federal Do Rio De Janeiro
    Inventors: Alysson Muotri, Paulo Andre Nobrega Marinho, Stevens Kastrup Rehen, Leda Dos Reis Castilho
  • Patent number: 9725700
    Abstract: The present invention provides three-dimensional microenvironment niches prepared from biomaterial compositions that supports growth and self renewal of stem cells. The invention also provides methods for inducing pluripotency in a somatic cell using chemical compounds, as well as methods for screening for compounds that can induce pluripotency in a somatic cell.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: August 8, 2017
    Assignee: DNAmicroarray, Inc.
    Inventor: Babak Esmaeli-Azad
  • Patent number: 9719067
    Abstract: The invention is directed to in vitro methods of inducing differentiation of anterior foregut endoderm and the enriched populations of anterior foregut endoderm produced by such methods. Such enriched populations are useful for studies of the molecular events that occur during differentiation and for generating cells for cell replacement therapy.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: August 1, 2017
    Assignee: Mount Sinai School of Medicine
    Inventors: Hans-Willem Snoeck, Michael Green
  • Patent number: 9719068
    Abstract: The generation of complex organ tissues from human embryonic and pluripotent stem cells (PSCs) remains a major challenge for translational studies. It is shown that PSCs can be directed to differentiate into intestinal tissue in vitro by modulating the combinatorial activities of several signaling pathways in a step-wise fashion, effectively recapitulating in vivo fetal intestinal development. The resulting intestinal “organoids” were three-dimensional structures consisting of a polarized, columnar epithelium surrounded by mesenchyme that included a smooth muscle-like layer. The epithelium was patterned into crypt-like SOX9-positive proliferative zones and villus-like structures with all of the major functional cell types of the intestine. The culture system is used to demonstrate that expression of NEUROG3, a pro-endocrine transcription factor mutated in enteric anendocrinosis is sufficient to promote differentiation towards the enteroendocrine cell lineage.
    Type: Grant
    Filed: May 6, 2011
    Date of Patent: August 1, 2017
    Assignee: Children's Hospital Medical Center
    Inventors: James M. Wells, Jason R. Spence, Aaron M. Zorn, Noah F. Shroyer
  • Patent number: 9719066
    Abstract: The present disclosure is related to methods for forming a stem cell bank. The methods include obtaining a first stem cell from a multi-cell fertilized embryo, expanding the first stem cell into two or more descendant stem cells, and storing at least one of the descendant stem cells to form the stem cell bank. Also disclosed is a kit that can be used for making the stem cell bank during in vitro fertilization. If desired, the HLA serotype of the stem cells can be determined prior to storage.
    Type: Grant
    Filed: September 6, 2013
    Date of Patent: August 1, 2017
    Assignee: BIOLAMINA AB
    Inventors: Karl Tryggvason, Kristian Tryggvason, Outi Hovatta
  • Patent number: 9713625
    Abstract: Described herein are methods for diagnosing ovarian cancer. In particular, certain microRNAs are useful to the response to chemotherapy of ovarian cancer patients.
    Type: Grant
    Filed: January 6, 2016
    Date of Patent: July 25, 2017
    Assignee: The Ohio State University
    Inventors: Carlo M. Croce, Andrea Vecchione
  • Patent number: 9714415
    Abstract: A method for stem or progenitor cell culture. More precisely, the invention relates to a method for cell culture using one or more I?I (inter-alpha trypsin inhibitor or Inter-alpha inhibitor) protein(s) or part(s) thereof as a component in a cell culture media or a coating on a cell culture surface material. Furthermore the invention relates to a cell culture media and a cell culture coating/matrix provided with one or more I?I proteins(s) or part(s) thereof.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: July 25, 2017
    Assignee: GE Healthcare Bio-Sciences AB
    Inventors: Sara Pijuan Galito, Christoffer Tamm, Cecilia Anneren
  • Patent number: 9706759
    Abstract: Non-human animals, tissues, cells, and genetic material are provided that comprise a modification of an endogenous non-human heavy chain immunoglobulin sequence and that comprise an ADAM6 activity functional in a mouse, wherein the non-human animals express a human immunoglobulin heavy chain variable domain and a cognate human immunoglobulin ? light chain variable domain.
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: July 18, 2017
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Lynn Macdonald, Cagan Gurer, Karolina A. Hosiawa, Sean Stevens, Andrew J. Murphy
  • Patent number: 9708589
    Abstract: The invention relates to biotechnology and provides novel compositions and methods for sequence-specific or sequence-directed transcription activator-like effector recombinases. The invention also provides novel plant transformation vectors and expression cassettes, which include novel combinations of chimeric recombinases with plant expression and transformation elements. Methods for gene-targeting, DNA sequence removal, and molecular breeding are also provided.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: July 18, 2017
    Assignee: Monsanto Technology LLC
    Inventors: Jonathan C. Lamb, Artem G. Evdokimov
  • Patent number: 9707278
    Abstract: Methods of decreasing an immune suppressive response, increasing an immune stimulating response, or a combination thereof in a subject in need thereof are disclosed. The methods typically include administering the subject a composition including a compound that reduces the bioavailability of Akt3 in an amount effective to reduce the immune suppressive response, increase the immune stimulating response, or a combination thereof in the subject. Methods of increasing an immune suppressive response, decreasing an immune stimulating response, or a combination thereof in a subject in need thereof are also disclosed. The methods typically include administering the subject a composition including a compound that increases the bioavailability of Akt3 in an amount effective to increase the immune suppressive response, decrease the immune stimulating response, or a combination thereof in the subject.
    Type: Grant
    Filed: April 17, 2015
    Date of Patent: July 18, 2017
    Assignee: Augusta University Research Institute, Inc.
    Inventors: Samir N. Khleif, Mikayel Mkrtichyan
  • Patent number: 9701753
    Abstract: Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position 114, according to Kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: July 11, 2017
    Assignee: GENZYME CORPORATION
    Inventors: Clark Pan, Huawei Qiu, Pradeep Dhal, Bo Chen, Diego Gianolio
  • Patent number: 9700521
    Abstract: The invention relates to a pharmaceutical formulation for sustained delivery of a therapeutic agent, preferably a protein, polypeptide, an antibody or an antibody fragment, comprising one or more gel forming peptides wherein the formulation exhibits sustained delivery for at least two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, ten weeks, eleven weeks, twelve weeks or more. In one embodiment, the invention relates to a formulation comprising self-assembling peptides that undergo sol-gel transition in the presence of an electrolyte solution such as biological fluids and salts. The formulation can provide sustained release of antibody and antibody fragments, in particular, IgG. Antibody diffusivities can be decreased with increasing hydrogel nanofiber density, providing a means to control the release kinetics.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: July 11, 2017
    Assignee: Massachusetts Institute of Technology
    Inventors: Sotirios Koutsopoulos, Shuguang Zhang
  • Patent number: 9695400
    Abstract: We provide IDH1 gene-defective cell lines (e.g., IDH1R132H heterozygous and IDH1R132H homozygous) derived from dissociated human astrocytoma samples. The cells can be used alone or in combination with each other or other cell types as a tool for determining the impact of IDH1R132H on cellular biology, tumorigenesis, and metabolic profiles. The cell lines may be used to test and identify therapeutic targets and to screen for molecular therapeutic agents.
    Type: Grant
    Filed: October 24, 2011
    Date of Patent: July 4, 2017
    Assignee: Duke University
    Inventors: Hai Yan, Darell Bigner, Genglin Jin
  • Patent number: 9695410
    Abstract: Provided are isolated complexes comprising a major histocompatibility complex (MHC) class II and a type I diabetes-associated GAD autoantigenic peptide, the isolated complex having a structural conformation which enables isolation of a high affinity entity which comprises an antigen binding domain capable of specifically binding to a native conformation of a complex composed of the MHC class II and the type I diabetes-associated GAD autoantigenic peptide; and isolated high affinity entities comprising an antigen binding domain capable of specifically binding the complex, wherein the isolated high affinity entity does not bind to the MHC class II in an absence of the diabetes-associated GAD autoantigenic peptide, wherein the isolated high affinity entity does not bind to the diabetes-associated GAD autoantigenic peptide in an absence of the MHC class II; and methods and kits using same for diagnostic and therapeutic purposes.
    Type: Grant
    Filed: July 14, 2011
    Date of Patent: July 4, 2017
    Assignee: Technion Research & Development Foundation Limited
    Inventors: Yoram Reiter, Rony Dahan
  • Patent number: 9688961
    Abstract: The present invention relates to testis somatic cell-derived pluripotent stem cells, and more particularly, to pluripotent adult stem cells which exhibit a positive immune reaction to both CD34 and CD73 and which are derived from testis somatic cells. The present invention further relates to a method for producing the testis somatic cell-derived pluripotent stem cells, and to a pharmaceutical composition including same for the treatment of erectile dysfunction.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: June 27, 2017
    Assignee: SUNGKWANG MEDICAL FOUNDATION
    Inventors: Dong-Ryul Lee, Won-Yun Choi, Tae-Ki Yoon
  • Patent number: 9688617
    Abstract: The present disclosure provides a photoreactive synthetic regulator of protein function. The present disclosure further provides a light-regulated polypeptide that includes a subject synthetic regulator. Also provided are cells and membranes comprising a subject light-regulated polypeptide. The present disclosure further provides methods of modulating protein function, involving use of light.
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: June 27, 2017
    Assignee: The Regents of the University of California
    Inventors: Dirk Trauner, Ehud Y. Isacoff, Richard H. Kramer, Matthew R. Banghart, Doris L. Fortin, Alexandre Mourot
  • Patent number: 9670446
    Abstract: The present invention relates to large-scale bioreactors having at least two impellers, large-scale bioreactor systems and methods for the large scale cultivation and propagation of mammalian cells using these bioreactors.
    Type: Grant
    Filed: October 16, 2015
    Date of Patent: June 6, 2017
    Assignee: Lonza Biologics PLC
    Inventor: Mohsan Khan
  • Patent number: 9670458
    Abstract: The present invention provides highly advantageous and efficient methods for spermatogonial stem cell (SSC) transfer for the generation of animals having valuable traits or genetic background.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: June 6, 2017
    Assignee: AGGENETICS, INC.
    Inventors: James West, Susan M. Majka
  • Patent number: 9663560
    Abstract: Improvement of fiber quality of Upland cultivars (Gossypium hirsutum), while maintaining early maturity and productivity, is a fundamental problem in conventional cotton breeding. Phytochromes play a fundamental role in plant development, flowering and cotton fiber length. Targeted RNAi of PHYA1 genes in cotton suppressed expression of PHYA1 and/or PHYB, resulting in over-expression of the remaining PHYA2/B/C/E genes. This altered expression induced a number of phytochrome-associated phenotypes, including increased root length and mass, increased anthocyanin-pigment, vigorous shoot development and vegetative growth, early flowering, early boll maturity, increased fiber length and increased seed cotton yield compared to control plants. These RNAi phenotypes were stably inherited and expressed through four generations (T0-3) and were transferable from RNAi Coker-312 plants to Upland cultivars via conventional hybridization.
    Type: Grant
    Filed: April 12, 2012
    Date of Patent: May 30, 2017
    Assignees: The United States of America, as represented by the Secretary of Agriculture, Agriculture Center of Genomics and Bioinformatics, Academy of Sciences Of Uzbekistan, The Texas A & M University System
    Inventors: Ibrokhim Y. Abdurakhmonov, Zabardast T. Buriev, Abdusattor Abdukarimov, Sukumar Saha, Johnie N. Jenkins, Alan E. Pepper
  • Patent number: 9663810
    Abstract: Polypeptide preparations having target levels of glycans, and methods of producing such polypeptide preparations using putrescine, are described.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: May 30, 2017
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventor: Holly Prentice
  • Patent number: 9651553
    Abstract: The present specification discloses a retargeted endopeptidase pharmaceutical wherein the activity has been determined by the methods disclosed.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: May 16, 2017
    Assignee: Allergan, Inc.
    Inventors: Joanne Wang, Hong Zhu, Dianne D. Hodges, Ester Fernandez-Salas
  • Patent number: 9650663
    Abstract: This invention relates to a sensor for detecting a stem cell differentiation, including (a) an electrode; and (b) a substrate of an alkaline phosphatase. The phosphorylation or dephosphorylation of the substrate for an alkaline phosphatase as a stem cell undifferentiation marker which dephosphorylates its substrate may be measured using an electrical signal in the present sensor. Therefore, the sensor of the present invention enables to electrically detect a stem cell status in a high-throughput manner and to determine the stem cell differentiation.
    Type: Grant
    Filed: November 27, 2013
    Date of Patent: May 16, 2017
    Assignee: Industry-University Cooperation Foundation Sogang University
    Inventors: Jeong-Woo Choi, Cheol-Heon Yea
  • Patent number: 9637787
    Abstract: A 3D organotypic culture which phenocopies aggressive, invasive cancer and methods of use thereof are provided.
    Type: Grant
    Filed: September 4, 2014
    Date of Patent: May 2, 2017
    Assignee: The Trustees of the University of Pennsylvania
    Inventor: Anil K. Rustgi
  • Patent number: 9631175
    Abstract: A method of generating neural and glial cells is provided. The method comprising growing human stem cells under conditions which induce differentiation of said human stem cells into the neural and glial cells, said conditions comprising the presence of retinoic acid and an agent capable of down-regulating Bone Morphogenic Protein activity.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: April 25, 2017
    Assignee: Yeda Research and Development Co. Ltd. at the Weizmann Institute of Science
    Inventors: Michel Revel, Judith Chebath, Michal Izrael, Rosalia Kaufman
  • Patent number: 9631172
    Abstract: The present invention relates to a method for manufacturing a three-dimensional (3D) biomimetic scaffold that exploits the use of electrical fields and electrical insulating materials to pattern previously polymerized hydro gels with different molecules and/or macromolecular entities. The invention also relates to the 3D-biomimetic scaffolds obtained and to the uses and applications thereof.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: April 25, 2017
    Assignee: Queen Mary University of London
    Inventors: Alvaro Mata Chavarria, Juan Pablo Aguilar
  • Patent number: 9631216
    Abstract: The present disclosure relates to a method of reducing heterogeneity in antibodies during culturing, wherein the heterogeneity is due to proportion of charge variant of the antibody. The disclosure also comprises a process of growing cells in a cell culture system that results in antibodies with the reduced heterogeneity. In one embodiment antibody heterogeneity is reduced by the addition of divalent transitional metal ions such as zinc (Zn2+) to the cell culture medium. In another embodiment antibody heterogeneity is reduced by decreasing the osmolality of the cell culture medium.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: April 25, 2017
    Assignee: Biocon Research Limited
    Inventors: Ruchika Srivastava, Sneha Lakshmandas Hemdev, Ankur Bhatnagar, Saravanan Desan, Anuj Goel, Harish Iyer
  • Patent number: 9631176
    Abstract: The present invention provides a method for preparing homogeneous stem cells and/or precursor cells in a large amount, in a simple and efficient manner, from human (in particular, the subject per se). The present invention further provides a method for preparing tissue implant or graft in a large amount by the use of the stem cells and/or precursor cells of the present invention. The present inventors have unexpectedly discovered that an aspirate from liposuction contains a large number of stem cells and have established a method for preparing stem cells from such an aspirate from liposuction, and thereby achieved the above-mentioned object.
    Type: Grant
    Filed: November 4, 2004
    Date of Patent: April 25, 2017
    Assignee: BIOMASTER, INC.
    Inventors: Kotaro Yoshimura, Daisuke Matsumoto
  • Patent number: 9625444
    Abstract: The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the normal tissues that interact with vaccines in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interaction with the immune system.
    Type: Grant
    Filed: March 20, 2014
    Date of Patent: April 18, 2017
    Assignees: SANOFI PASTEUR VAXDESIGN CORPORATION, THE SCRIPPS RESEARCH INSTITUTE, MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH, MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY
    Inventors: William L Warren, Heather Fahlenkamp, Russell Higbee, Anatoly Kachurin, Conan Li, Mike Nguyen, Robert Parkhill, Guzman Sanchez-Schmitz, Darrell J. Irvine, Gwendalyn J. Randolph, Nir Hacohen, Bruce Torbett
  • Patent number: 9622459
    Abstract: Non-human animals, tissues, cells, and genetic material are provided that comprise a modification of an endogenous non-human heavy chain immunoglobulin sequence and that comprise an ADAM6 activity functional in a mouse, wherein the non-human animals express a human immunoglobulin heavy chain variable domain and a cognate human immunoglobulin ? light chain variable domain.
    Type: Grant
    Filed: July 26, 2013
    Date of Patent: April 18, 2017
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Lynn Macdonald, Cagan Gurer, Karolina A. Meagher, Sean Stevens, Andrew J. Murphy
  • Patent number: 9617539
    Abstract: Certain embodiments are directed to methods and compounds for inhibiting UBE3A-ATS, the endogenous antisense transcript of ubiquitin protein ligase E3A (UBE3A). Such methods and compounds are useful for inducing expression of paternal UBE3A in cells and animals.
    Type: Grant
    Filed: June 25, 2013
    Date of Patent: April 11, 2017
    Assignees: Ionis Pharmaceuticals, Inc., Baylor College of Medicine
    Inventors: Frank Rigo, Amanda Ward, Linyan Meng, Arthur L. Beaudet
  • Patent number: 9617542
    Abstract: Disclosed is a dsRNA construct that relates to a method to control Lepidopteran moths via double-stranded RNA interference of the PBAN/Pyrokinin gene.
    Type: Grant
    Filed: December 13, 2011
    Date of Patent: April 11, 2017
    Assignee: The United States of America, as representd by The Secretary of Agriculture
    Inventors: Robert K. Vander Meer, Man-Yeon Choi
  • Patent number: 9612250
    Abstract: The present invention relates to method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200, wherein the compound to be detected and/or quantified is a chemically complex molecule, wherein said chemically complex molecule is substituted with at least two groups —R, wherein each R group means independently —OH, —OP(O)(OH)2 or —P(O)(OH)2, with the proviso that at least two R are independently selected from —P(O)(OH)2 and —OP(O)(OH)2, wherein the compound or compounds to be detected and/or quantified are within a biological matrix, wherein said biological matrix is a biological fluid, a biological tissue, stomach contents, intestine contents, stool sample or a culture cells, wherein the method comprises performing a chromatography and identifying the retention time and/or the intensity of the signal by means of a mass or radioactivity detector.
    Type: Grant
    Filed: October 8, 2012
    Date of Patent: April 4, 2017
    Assignee: Laboratorios Sanifit, S.L.
    Inventors: Joan Perello Bestard, Ciriaco Maraschiello de Zuani, Irene Lentheric, Paula Mendoza de las Heras, Fernando Tur Espinosa, Eva Tur Tur, Maximo Encabo Alarcon, Eva Martin Becerra, Maria de Mar Benito Amengual, Bernat Isern Amengual
  • Patent number: 9611497
    Abstract: The invention relates to methods for the detection of a specific sequence of RNA in a cell or tissue sample. The invention also relates to methods to enzymatically manipulate the RNA in a crude cell lysate in a number of applications.
    Type: Grant
    Filed: May 3, 2012
    Date of Patent: April 4, 2017
    Assignee: Applied Biosystems, LLC
    Inventors: Brittan Pasloske, Quoc Hoang
  • Patent number: 9612306
    Abstract: A method for producing a biomarker indicative of a repetitive head injury in a subject using a magnetic resonance imaging (MRI) system is provided. Two-dimensional spectroscopic data is acquired from a subject using an MRI system. From the two-dimensional spectroscopic data, a two-dimensional spectrum is produced. The two-dimensional spectrum contains spectral information indicated by a first spectral dimension and a second spectral dimension. Such a two-dimensional spectrum may include diagonal peaks and off-diagonal, or cross-peaks. In such an instance, each cross peak may indicate, for example, scalar coupling between the two protons it connects on the diagonal. However, depending on the type of method used, different types of coupling may also be present. Using the two-dimensional spectrum, a biomarker indicative of repetitive head injury in the subject is identified, and may be used to produce a report indicating a status or regression of a neurological dysfunction.
    Type: Grant
    Filed: November 28, 2011
    Date of Patent: April 4, 2017
    Assignee: Brigham and Women's Hospital, Inc.
    Inventors: Alexander Lin, Carolyn Mountford, Saadallah Ramadan, Robert Stern
  • Patent number: 9603894
    Abstract: The invention provides a solution to the problem of delivering molecules in a physiologically relevant manner to direct cell fate. For example, a Notch ligand molecule is presented in a microenvironment that mimics the environment encountered in vivo. Accordingly, the invention features a cell delivery vehicle comprising a biocompatible hydrogel or polymer and a composition that binds to a Notch receptor and methods of directing cell fate, e.g., stem cell differentiation, using such compositions.
    Type: Grant
    Filed: November 8, 2011
    Date of Patent: March 28, 2017
    Assignee: President and Fellows of Harvard College
    Inventors: Lan Cao, Kamal H. Bouhadir, David J. Mooney
  • Patent number: 9598694
    Abstract: The present invention relates to the involvement of miR function in the development of age-related macular degeneration (AMD). It is shown that miR-23, miR-24 and/or miR-27 are involved in pathologic neovascularization in AMD, and that agonism (miR-24) and inhibition (miR23/27) of the function of these molecules blocks events contributing to development and progression of disease.
    Type: Grant
    Filed: May 2, 2013
    Date of Patent: March 21, 2017
    Assignees: The Board of Regents of the University of Texas System, The Administrators of the Tulane Educational Fund
    Inventors: Shusheng Wang, Eric Olson, Qinbo Zhou
  • Patent number: 9592278
    Abstract: Devices and methods for treating defects in connective tissue are provided along with methods for making such devices. The devices can include enzyme-activated acellular tissue matrices that facilitate regrowth of the damaged tissue.
    Type: Grant
    Filed: February 26, 2013
    Date of Patent: March 14, 2017
    Assignee: LifeCell Corporation
    Inventors: Wenquan Sun, Xiaohua Yu
  • Patent number: 9587212
    Abstract: The present invention provides an apparatus and methods for producing tetrahydrocannabinolic acid (THCA), cannabichromenic acid (CBCA) and cannabichromenic acid (CBCA) in different ratios. The apparatus comprises: (i) a bioreactor comprising (a) an automated supply system configured to deliver a first automated supply of cannabigerolic acid (CBGA), a cannabinoid acid synthase, and a reaction mixture; and (b) a second automated system to cease the reaction; (ii) a controller configured to modify a property of the reaction mixture to produce the desired products; and (iii) an extractor configured to recover the tetrahydrocannabinolic acid (THCA), cannabichromenic acid (CBCA) or cannabidiolic acid (CBDA) and cannabichromenic acid.
    Type: Grant
    Filed: August 9, 2016
    Date of Patent: March 7, 2017
    Assignee: Full Spectrum Laboratories Limited
    Inventors: Robert Winnicki, Marc Donsky, Mingyang Sun, Richard Peet
  • Patent number: 9588106
    Abstract: Embodiments of the present invention provide an in vitro assay that measures cell monolayer permeability. The assay utilizes detection of a binding pair initially separated by the cell monolayer as a qualitative and quantitative measure of the permeability of the monolayer. In certain embodiments, the assay is performed in the presence of a test substance that may or may not affect cell permeability. In particular aspects, the assay is performed on a substrate that is elastic. One can also assay spatial resolution of local changes by visualizing regional variations of the cell monolayers.
    Type: Grant
    Filed: September 5, 2013
    Date of Patent: March 7, 2017
    Assignee: The University of Chicago
    Inventors: Oleksii Dubrovskyi, Konstantin Birukov
  • Patent number: 9585917
    Abstract: Disclosed herein are methods of producing pancreatic hormone-expressing cells by first differentiating pluripotent cells in cell culture so as to produce endodermal cells, the endodermal cells being competent to further differentiate into hormone-expressing cells capable of secreting at least one pancreatic hormone in response to a physiological signal, and then, transplanting the cultured endodermal cells into an organism, such as an organism in need of an endocrine cell therapy.
    Type: Grant
    Filed: August 8, 2011
    Date of Patent: March 7, 2017
    Assignee: ViaCyte, Inc.
    Inventors: Laura Martinson, Evert Kroon, Kevin D'Amour, Emmanuel Edward Baetge
  • Patent number: 9572815
    Abstract: In one aspect, the invention relates to pharmaceutical compositions comprising agents that activate the expression of Atoh1, or pharmaceutically acceptable salts, solvates, or polymorphs thereof; and agents that inhibit the expression of p27Kip1, or pharmaceutically acceptable salts, solvates, or polymorphs thereof, which are useful for inducing the formation of cochlear hair cells; and methods of treating hearing impairments or disorders using the compositions. In one aspect, the invention relates to pharmaceutical compositions comprising ?-catenin; and agents that activate the expression of Atoh1, or pharmaceutically acceptable salts, solvates, or polymorphs thereof. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: March 15, 2014
    Date of Patent: February 21, 2017
    Assignee: St. Jude Children's Research Hospital
    Inventors: Jian Zuo, Taosheng Chen, Brandon Walters, Bryan Kuo, Bradley Walters